Program
vicadrostat
Also written as “BI 690517”, “Vicadrostat” and “Vicadrostat + empagliflozin”.
In Boehringer Ingelheim's pipeline, Aldosterone synthase inhibitor / SGLT2 inhibitor
. Its studies are mostly in Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus, Type 2 · Diabetic Nephropathies · Liver Diseases, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 165 open or running | phase 3since May 10, 2024 | Sep 1, 2016 | Dec 11, 2026phase 1 · NCT07845630 |
- Named in Boehringer Ingelheim’s own pipeline as
Vicadrostat (BI 690517)
, phase 3, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 1, 2016.
- Jun 30, 2017Phase 1 study in HealthyNCT03206632 · 56 enrolled · Korea, Republic of
- Jul 20, 2018Phase 1 study in HealthyNCT03608072 · 36 enrolled · Japan
- Jan 5, 2022Phase 2 study in Renal Insufficiency, ChronicNCT05182840 · 714 enrolled · United States, Argentina, Australia and more
- Aug 24, 2022Phase 1 study in HealthyNCT05515588 · 14 enrolled · Netherlands
- Feb 8, 2023Phase 1 study in Liver DiseasesNCT05731908 · 28 enrolled · United States
- May 10, 2024Phase 3 study in Heart FailureNCT06424288 · 6,712 planned · United States, Argentina, Australia and more
- Jul 29, 2024Phase 3 study in Renal Insufficiency, ChronicNCT06531824 · 8,371 enrolled · United States, Argentina, Australia and more
- Apr 11, 2025Phase 2 study in Renal Insufficiency, ChronicNCT06926660 · 492 enrolled · United States, Argentina, Australia and more
- Apr 17, 2025Phase 3 study in Heart FailureNCT06935370 · 4,200 planned · United States, Argentina, Belgium and more
- Jun 17, 2025Phase 1 study in HealthyNCT07035457 · 15 enrolled · Germany
- Jul 11, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07064473 · 11,800 planned · United States, Argentina, Australia and more
- Aug 19, 2025Phase 1 study in HealthyNCT07133399 · 32 enrolled · Germany
- Apr 1, 2026Phase 1 study in HealthyNCT07513207 · 45 enrolled · Germany
- Sep 23, 2026Phase 1 study in HealthyNCT07845630 · 36 planned · Germany
Ahead
- Dec 11, 2026Primary completion: phase 1 study in HealthyNCT07845630
- Dec 31, 2026Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT06531824
- May 22, 2028Primary completion: phase 3 study in Heart FailureNCT06424288
- Feb 4, 2029Primary completion: phase 3 study in Heart FailureNCT06935370
TargetBeta
“Aldosterone synthase inhibitor / SGLT2 inhibitor”the company's pipeline, read by Claude · source
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07845630Healthy · Germany | 1 | Recruiting | Dec 11, 2026 | 36 |
| NCT07513207Healthy · Germany | 1 | Completed | Jul 24, 2026 | 45 |
| NCT07133399Healthy · Germany | 1 | Completed | Oct 22, 2025 | 32 |
| NCT07064473Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Recruiting | Dec 14, 2029 | 11,800 |
| NCT07035457Healthy · Germany | 1 | Completed | Aug 7, 2025 | 15 |
| NCT06935370Heart Failure · United States, Argentina, Belgium and more | 3 | Recruiting | Feb 4, 2029 | 4,200 |
| NCT06926660Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Aug 14, 2026 | 492 |
| NCT06531824Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 31, 2026 | 8,371 |
| NCT06424288Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | May 22, 2028 | 6,712 |
| NCT05731908Liver Diseases · United States | 1 | Completed | Apr 13, 2023 | 28 |
| NCT05515588Healthy · Netherlands | 1 | Completed | Nov 17, 2022 | 14 |
| NCT05182840Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 2 | Completed | Jun 19, 2023 | 714 |
| NCT03608072Healthy · Japan | 1 | Completed | Jan 31, 2019 | 36 |
| NCT03206632Healthy · Korea, Republic of | 1 | Completed | Oct 13, 2017 | 56 |
| NCT03165240Diabetic Nephropathies · Denmark, France, Germany and more | 1 | Completed | Apr 16, 2020 | 62 |
| NCT02891148Healthy · Germany | 1 | Completed | Dec 12, 2016 | 50 |
How it is read
Names in the registry
- “BI 690517”, 8 entries
- “Vicadrostat”, 5 entries
- “vicadrostat”, 2 entries
- “Vicadrostat + empagliflozin”, 1 entry
- “vicadrostat / empagliflozin combination 1”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 3 studies
- Heart Failure, 2 studies
- Diabetes Mellitus, Type 2, 1 study
- Diabetic Nephropathies, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.